Intraperitoneal Chemotherapy
Dextrose-Containing Carrier Solution for Hyperthermic Intraperitoneal Chemotherapy: Increased Intraoperative Hyperglycemia and Postoperative Complications.
Annals of Surgical Oncology 2020 April 19 [Link] Torphy RJ, Stewart C, Sharma P, Halpern AL, Oase K, Herter W, Bartsch C, Friedman C, Del Chiaro M, Schulick RD, Gleisner A, McCarter MD, Ahrendt SA Abstract PURPOSE:Intraoperative hyperglycemia is associated with infectious complications in general surgery patients. This study aimed to determine if the use…
Read MorePredictors and Outcomes of Surgery in Peritoneal Mesothelioma: an Analysis of 2000 Patients from the National Cancer Database.
Annals of Surgical Oncology 2020 January 31 [Link] Bijelic L, Darcy K, Stodghill J, Tian C, Cannon T Abstract INTRODUCTION: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare malignancy associated with poor outcomes. Recent reports have shown longer survival with radical surgery, usually combined with intraperitoneal chemotherapy. However, surgical interventions in these patients have not…
Read MoreIndications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
European Journal of Cancer 2020 January 24 [Link] Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T Abstract The purpose of the present review was to describe evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC), with cytoreductive surgery (CRS), in patients with a diagnosis of mesothelioma, appendiceal (including appendiceal mucinous neoplasm), colorectal, gastric,…
Read MoreLong-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma.
Surgical Endoscopy 2019 December 2 [Link] Mercier F, Jeremie G, Alyami M, Delphine V, Vahan K, Pascal R, Sylvie I, Guillaume P, Olivier G Abstract BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) provide long-term survival for low-grade pseudomyxoma peritonei (PMP) and multicystic peritoneal mesothelioma (MM). Feasibility of laparoscopic CRS-HIPEC has been reported for…
Read MoreIntraperitoneal delivery of chemotherapeutic agents for the treatment of peritoneal metastases: Current challenges and how to overcome them.
Expert Opinion on Drug Delivery 2019 November 14 [Link] Sugarbaker PH Abstract Introduction: Peritoneal metastases of cancer remains a major cause of an adverse outcome and death following surgical treatment of malignancies that occur within the abdomen and pelvis. The administration of a chemotherapy solution directly into the peritoneal space has been used to improve…
Read MoreMESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma.
Pleura and Peritoneum 2019 June 27 [Link] Sgarbura O, Gourgou S, Tosi D, Bakrin N, Bouazza N, Delaine S, De Forges H, Pocard M, Quénet F Abstract BACKGROUND: Malignant peritoneal mesothelioma (MPM) is a rare tumoral disease characterized by the diffuse involvement of the peritoneal serosa. The standard frontline treatment of MPM is cytoreductive surgery…
Read MoreLong term survival and perioperative propensity score matched outcomes of diaphragmatic resections compared to stripping in cytoreductive surgery + intra-peritoneal chemotherapy.
American Journal of Surgery 2019 June 23 [Link] Singh B, Singh G, Alzahrani N, Morris DL Abstract OBJECTIVES: To assess the impact of short and long term outcomes of diaphragm resection and repair in cyto-reductive surgery (CRS) and intra-peritoneal chemotherapy (IPC). METHODS: 1230 consecutive CRS/IPC procedures were performed between 1996 and 2018 in Sydney, Australia.…
Read MoreAdjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
BMJ Open 2019 May 14 [Link] de Boer NL, van Kooten JP, Burger JWA, Verhoef C, Aerts JGJV, Madsen EVE Abstract INTRODUCTION: Malignant peritoneal mesothelioma (MPM) is an uncommon but aggressive neoplasm and has a strong association with asbestos exposure. MPM has low survival rates of approximately 1 year even after (palliative) surgery and/or systemic chemotherapy.…
Read MoreEffect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma.
Annals of Surgical Oncology 2019 May 8 [Link] Ali YM, Sweeney J, Shen P, Votanopoulos K, McQuellon R, Duckworth K, Perry KC, Russell G, Levine EA Abstract INTRODUCTION: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) is an accepted treatment for peritoneal mesothelioma. In this study, we evaluated QOL after HIPEC for peritoneal mesothelioma. METHODS: This…
Read More50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience.
Annals of Surgical Oncology 2019 May 7 [Link] Letica-Kriegel AS, Leinwand JC, Sonett JR, Gorenstein LA, Taub RN, Chabot JA, Kluger MD Abstract BACKGROUND: The most common sites of malignant mesothelioma are the pleura and peritoneum, but little is known about the incidence, prognosis, or treatment of patients with disease in both cavities. Previous series…
Read More